Scholarlink

<p>The global COVID-19 pandemic has underscored the need for innovative vaccine strategies, including oral vaccines, to improve accessibility and enhance immunity. In this study, we explored a novel oral vaccine approach by using yeast surface display to express the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein on <i>Pichia pastoris</i> using SED1 as a carrier protein. The constructs included a fibritin foldon domain from bacteriophage T4 for trimerization and truncated flagellin from <i>Salmonella typhimurium</i> (FliC) as an adjuvant to boost immunogenicity. Three recombinant yeast constructs were designed and evaluated: construct I (RBD-SED1), construct II (RBD-foldon-SED1), and construct III (FliC-RBD-foldon-SED1). Structural integrity, proper folding, and trimerization (in construct III) were modeled and confirmed using ColabFold. These constructs were successfully expressed on the yeast surface and confirmed through fluorescence microscopy, flow cytometry, and ELISA. Oral immunization of BALB/c mice with the recombinant yeast significantly induced spike protein-specific IgG antibodies in serum and IgA in fecal samples, indicating strong humoral and mucosal immune responses. Notably, construct III induced the highest immune response. These findings suggest that yeast-based oral vaccines expressing trimerized SARS-CoV-2 spike protein RBD, combined with a peptide fragment from flagellin, as an immunomodulatory adjuvant, can elicit robust immunity, offering a promising alternative for future COVID-19 vaccination strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Oral yeast-displayed SARS-CoV-2 spike protein vaccine enhanced by trimerization and flagellin peptide

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月4日

查看全文
  • Tahereh Saveii,
  • Sareh Arjmand,
  • Ismaeil Haririan,
  • Navid Pourzardosht,
  • Reza H. Sajedi

摘要

The global COVID-19 pandemic has underscored the need for innovative vaccine strategies, including oral vaccines, to improve accessibility and enhance immunity. In this study, we explored a novel oral vaccine approach by using yeast surface display to express the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein on Pichia pastoris using SED1 as a carrier protein. The constructs included a fibritin foldon domain from bacteriophage T4 for trimerization and truncated flagellin from Salmonella typhimurium (FliC) as an adjuvant to boost immunogenicity. Three recombinant yeast constructs were designed and evaluated: construct I (RBD-SED1), construct II (RBD-foldon-SED1), and construct III (FliC-RBD-foldon-SED1). Structural integrity, proper folding, and trimerization (in construct III) were modeled and confirmed using ColabFold. These constructs were successfully expressed on the yeast surface and confirmed through fluorescence microscopy, flow cytometry, and ELISA. Oral immunization of BALB/c mice with the recombinant yeast significantly induced spike protein-specific IgG antibodies in serum and IgA in fecal samples, indicating strong humoral and mucosal immune responses. Notably, construct III induced the highest immune response. These findings suggest that yeast-based oral vaccines expressing trimerized SARS-CoV-2 spike protein RBD, combined with a peptide fragment from flagellin, as an immunomodulatory adjuvant, can elicit robust immunity, offering a promising alternative for future COVID-19 vaccination strategies.